Monday, October 04, 2021 7:36:40 AM
7:21 am ET October 4, 2021 (Dow Jones) Print
By Matt Grossman
Xenon Pharmaceuticals Inc.'s XEN1101 drug achieved positive results in a Phase 2b trial studying its use as an adjunctive treatment for focal epilepsy, the company said Monday.
Compared with a placebo, the drug achieved a statistically significant reduction from the baseline in monthly focal seizure frequency, meeting the study's primary efficacy endpoint.
More than half of patients who received the highest dose of the medication studied experienced a greater-than-50% reduction in seizure frequency, Xenon said. At the median, participants had been experiencing a baseline level of 13.5 seizures per month before the study.
Xenon Chief Executive Ian Mortimer said that the results support an "attractive clinical profile" for the drug. Data from the study have also encouraged Xenon's plans to additionally develop the drug for the treatment of major depressive disorder and for other types of epilepsy, he said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 04, 2021 07:21 ET (11:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
XENE
New York Yankees and Duke Basketball
Recent XENE News
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference • GlobeNewswire Inc. • 05/07/2024 08:01:00 PM
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 05/02/2024 08:01:00 PM
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/16/2024 12:30:00 PM
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 08:01:00 PM
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days • GlobeNewswire Inc. • 03/12/2024 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 11:47:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:31:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:28:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:27:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 12:04:19 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 12:03:52 AM
- Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 • GlobeNewswire Inc. • 03/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:10:54 PM
- Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 09:01:00 PM
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/22/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:12:03 PM
- Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:41:00 PM
- Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 12/04/2023 09:16:53 PM
- Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) • GlobeNewswire Inc. • 12/02/2023 05:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/30/2023 09:18:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 09:15:24 PM
- Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering • GlobeNewswire Inc. • 11/30/2023 03:51:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/29/2023 10:05:41 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM